Gilead exercised a $45 million option on Kymera Therapeutics’ preclinical molecular-glue degrader program, positioning the company to advance an oral CDK2 degrader into IND-enabling work. Under the agreement, Gilead gains global rights to KT-200, a candidate designed to degrade CDK2 with low-nanomolar activity. The move more than doubles Kymera’s total proceeds from the partnership and sets up potential development, regulatory, and commercial milestones of up to $665 million. Gilead is expected to run IND-enabling studies with a stated goal of filing to test the candidate in humans next year. Kymera’s differentiation is based on molecular-glue mechanism rather than conventional small-molecule kinase inhibition. The report notes mounting industry interest in CDK2 in the wake of uneven outcomes with CDK4/6 inhibitors and the search for better-controlled next steps in oncology settings.